

Tumor infiltrating lymphocytes are prognostic in triple
predictive for trastuzumab benefit in early breast cancer

Annals of Oncology

25, 1544-1550

DOI: [10.1093/annonc/mdu112](https://doi.org/10.1093/annonc/mdu112)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e115103.	1.1	182
2	Tumor Infiltrating Lymphocytes – The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. Journal of Carcinogenesis & Mutagenesis, 2014, 05, .	0.3	3
3	Oncogene addiction and immunity. Current Opinion in Oncology, 2014, 26, 562-567.	1.1	19
4	Pre-operative prognostic nutritional index predicts the outcomes for triple-negative breast cancer. Tumor Biology, 2014, 35, 12165-12171.	0.8	43
5	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Research and Treatment, 2014, 148, 511-523.	1.1	34
6	Histological Analysis of CD8 ⁺ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Frontiers in Immunology, 2014, 5, 632.	2.2	29
7	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. Clinical Cancer Research, 2014, 20, 6242-6246.	3.2	15
8	Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 2014, 25, 1536-1543.	0.6	610
9	Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. Immunotherapy, 2014, 6, 803-805.	1.0	6
10	PD-L1 expression and tumor-infiltrating lymphocytes. OncoImmunology, 2014, 3, e29288.	2.1	60
11	The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2014, 148, 467-476.	1.1	205
12	Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Medicine, 2014, 12, 132.	2.3	65
13	Immunoscore breast cancer: TILs remember what they target. Annals of Oncology, 2014, 25, 1455-1456.	0.6	15
14	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. Cancer Treatment Reviews, 2014, 40, 1192-1198.	3.4	51
15	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. Oncology Letters, 2015, 10, 1079-1086.	0.8	14
16	Tumor Heterogeneity in Breast Cancer. Advances in Anatomic Pathology, 2015, 22, 294-302.	2.4	12
17	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer: Basic and Clinical Research, 2015, 9s2, BCBCR.S29425.	0.6	4
18	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. Npj Breast Cancer, 2015, 1, .	2.3	0

#	ARTICLE	IF	CITATIONS
19	Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy. <i>BMC Cancer</i> , 2015, 15, 1027.	1.1	49
20	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. <i>BMC Cancer</i> , 2015, 15, 697.	1.1	3
21	The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 168.	1.8	40
22	An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 131.	2.2	81
23	<i>CCR</i> 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancerâ€”Where Did It Start and Where Are We Now?. <i>Clinical Cancer Research</i> , 2015, 21, 4743-4746.	3.2	23
24	CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4027-4029.	3.2	4
25	Triple-negative Breast Carcinoma. <i>Advances in Anatomic Pathology</i> , 2015, 22, 306-313.	2.4	13
26	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015, 6, 5449-5464.	0.8	424
27	Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions. <i>Current Molecular Pharmacology</i> , 2015, 7, 4-21.	0.7	23
28	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015, 6, 13506-13519.	0.8	105
30	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2â€”Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	0.8	863
31	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1698-1704.	0.6	244
32	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1298-1299.	0.8	32
33	Immunotherapy of Breast Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 30-43.	0.1	27
34	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 190-202.	0.5	0
35	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	1.1	75
36	Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. <i>Current Breast Cancer Reports</i> , 2015, 7, 203-209.	0.5	2
37	Potential Therapeutic Targets in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 215-223.	0.5	1

#	ARTICLE	IF	CITATIONS
38	The role of inflammation in progression of breast cancer: Friend or foe? (Review). <i>International Journal of Oncology</i> , 2015, 47, 797-805.	1.4	52
39	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 232-241.	0.5	0
40	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
41	Building immunity to cancer with radiation therapy. <i>Cancer Letters</i> , 2015, 368, 198-208.	3.2	69
42	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	3.3	118
43	Are Immune Signatures a Worthwhile Tool for Decision Making in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 673-675.	0.8	5
44	Adjuvant systemic therapy in breast cancer: quo vadis?. <i>Annals of Oncology</i> , 2015, 26, 1629-1634.	0.6	18
45	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 847-856.	1.9	1,787
46	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. <i>Current Breast Cancer Reports</i> , 2015, 7, 59-70.	0.5	1
47	Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 619-627.	1.1	58
48	The Evolving Landscape of HER2 Targeting in Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1154.	3.4	107
49	Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. <i>American Journal of Clinical Pathology</i> , 2015, 144, 278-288.	0.4	103
50	Fundamental Principles of Cancer Biology: Does It Have Relevance to the Perioperative Period?. <i>Current Anesthesiology Reports</i> , 2015, 5, 250-256.	0.9	7
51	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
52	Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1407-1409.	0.8	10
53	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	0.9	27
55	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <i>Breast Cancer Research</i> , 2015, 17, 43.	2.2	248
56	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449

#	ARTICLE	IF	CITATIONS
57	Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 969-971.	0.8	25
58	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101
59	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
60	Neoadjuvant treatment of breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 85-91.	0.9	14
61	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1297-1298.	0.8	9
62	Anti-“PD-1 Therapy in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 466-473.	0.8	41
63	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
64	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
65	Neoadjuvant treatment of breast cancer “ Clinical and research perspective. <i>Breast</i> , 2015, 24, S73-S77.	0.9	40
66	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 822-846.	4.0	242
67	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , 2015, 13, 202.	2.3	177
68	Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 239-249.	1.1	27
69	Immunity and HER2-positive disease: never stop questioning. <i>Annals of Oncology</i> , 2015, 26, 2361-2362.	0.6	2
70	Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 432-439.	1.1	8
71	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015, 21, 1128-1138.	15.2	268
72	Emerging Predictive Biomarkers of Response to Platinum Therapy in Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 224-231.	0.5	0
73	Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development. <i>Current Breast Cancer Reports</i> , 2015, 7, 151-160.	0.5	0
74	Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. <i>Breast</i> , 2015, 24, S143-S148.	0.9	18

#	ARTICLE	IF	CITATIONS
75	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
76	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. <i>Modern Pathology</i> , 2015, 28, 1415-1427.	2.9	36
77	Breast cancer and immunology: biomarker and therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1215-1222.	1.1	9
78	A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. <i>Breast</i> , 2015, 24, S23-S25.	0.9	3
79	Neoadjuvant clinical trial designs: Challenges of the genomic era. <i>Breast</i> , 2015, 24, S88-S90.	0.9	3
80	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 315ra188.	5.8	261
81	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. <i>Molecular Oncology</i> , 2015, 9, 2054-2062.	2.1	85
82	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
83	A prognostic index for locoregional recurrence after neoadjuvant chemotherapy. <i>Ecancermedalscience</i> , 2016, 10, 647.	0.6	1
84	Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. <i>Journal of Cancer</i> , 2016, 7, 1095-1104.	1.2	73
85	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 20282-20292.	0.8	28
86	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	1.8	85
87	The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5567-5575.	1.0	113
88	Restraint and Social Isolation Stressors Differentially Regulate Adaptive Immunity and Tumor Angiogenesis in a Breast Cancer Mouse Model. <i>Cancer and Clinical Oncology</i> , 2016, 6, 12.	0.2	27
89	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	1.1	8
90	Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histologyâ€“Genomic Integration Analysis. <i>PLoS Medicine</i> , 2016, 13, e1001961.	3.9	101
91	Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002194.	3.9	473
92	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. <i>PLoS ONE</i> , 2016, 11, e0167397.	1.1	9

#	ARTICLE	IF	CITATIONS
93	Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. <i>Journal of Thoracic Disease</i> , 2016, 8, E833-E835.	0.6	26
94	Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 385.	0.8	2
95	Triple-negative breast cancer: treatment challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 93.	1.0	201
96	The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0161731.	1.1	15
97	Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. <i>International Journal of Cancer</i> , 2016, 138, 2274-2280.	2.3	45
98	Targeting the programmed cell death-1 pathway in breast and ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 142-147.	0.9	47
99	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	1.1	100
100	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	1.1	16
101	I-SPY 2 – Toward More Rapid Progress in Breast Cancer Treatment. <i>New England Journal of Medicine</i> , 2016, 375, 83-84.	13.9	47
102	Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 552-555.	1.0	5
103	Inflammatory immune infiltration in human tumors: Role in pathogenesis and prognostic and diagnostic value. <i>Biochemistry (Moscow)</i> , 2016, 81, 1261-1273.	0.7	10
104	Triple-Negative Breast Cancer. , 2016, , 71-80.		9
105	Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 227.	1.8	56
106	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <i>Breast Care</i> , 2016, 11, 385-390.	0.8	20,872
107	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
108	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 121.	2.2	89
109	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 336-342.	0.5	9
110	Immune DNA signature of T-cell infiltration in breast tumor exomes. <i>Scientific Reports</i> , 2016, 6, 30064.	1.6	30

#	ARTICLE	IF	CITATIONS
111	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. <i>Cancer Science</i> , 2016, 107, 1730-1735.	1.7	125
112	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 651-662.	2.0	91
113	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
114	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5747-5754.	3.2	158
115	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 705-719.	1.0	61
116	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. <i>Cancer Treatment Reviews</i> , 2016, 46, 9-19.	3.4	84
117	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 117-131.	1.1	18
118	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	2.2	90
119	A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. <i>Clinical Cancer Research</i> , 2016, 22, 4133-4144.	3.2	19
120	Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer. <i>Breast Care</i> , 2016, 11, 96-100.	0.8	33
121	Prolactin-Inducible Protein: From Breast Cancer Biomarker to Immune Modulator—Novel Insights from Knockout Mice. <i>DNA and Cell Biology</i> , 2016, 35, 537-541.	0.9	21
122	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
123	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
124	Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. <i>Current Problems in Cancer</i> , 2016, 40, 151-162.	1.0	18
125	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 205-207.	3.4	50
126	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. <i>Annals of Oncology</i> , 2016, 27, 1867-1873.	0.6	109
127	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 685-695.	1.1	20
128	Spatial Heterogeneity in the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026583.	2.9	194

#	ARTICLE	IF	CITATIONS
129	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. <i>International Journal of Cancer</i> , 2016, 138, 87-97.	2.3	136
130	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175
131	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
132	Current and emerging therapies of HER2-positive metastatic breast cancer. <i>Breast</i> , 2016, 29, 170-177.	0.9	20
133	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 360-374.	1.4	37
134	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. <i>Npj Breast Cancer</i> , 2016, 2, 16022.	2.3	21
135	Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. <i>British Journal of Surgery</i> , 2016, 103, 845-854.	0.1	88
136	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24
137	Biology and Management of Patients With Triple-Negative Breast Cancer. <i>Oncologist</i> , 2016, 21, 1050-1062.	1.9	220
138	Immunothérapie et cancer du sein. <i>Oncologie</i> , 2016, 18, 551-558.	0.2	2
139	Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. <i>Oncolimmunology</i> , 2016, 5, e1248015.	2.1	48
140	Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. <i>Scientific Reports</i> , 2016, 6, 36231.	1.6	27
141	Clinical significance of tumor-infiltrating lymphocytes in breast cancer. , 2016, 4, 59.		530
142	Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic Approach. <i>Biomedical Engineering and Computational Biology</i> , 2016, 7s2, BECB.S38244.	0.8	12
143	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34540.	0.6	121
144	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
145	Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients. <i>Current Opinion in Oncology</i> , 2016, 28, 476-483.	1.1	6
146	Immunotherapy in Breast Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 335-345.	0.8	14

#	ARTICLE	IF	CITATIONS
147	Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data. <i>Current Breast Cancer Reports</i> , 2016, 8, 73-79.	0.5	6
148	The Challenge to Overcome Triple-Negative Breast Cancer Heterogeneity. , 2016, , 247-261.		0
149	Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 1-9.	1.1	45
150	Identification of stromal ColX±1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. <i>BMC Cancer</i> , 2016, 16, 274.	1.1	42
151	Les traitements adjuvants des cancers du sein : derniÃres avancÃes et perspectives pour des cancers trÃs diffÃrents. <i>Oncologie</i> , 2016, 18, 120-127.	0.2	1
152	No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014. <i>Journal of Surgical Oncology</i> , 2016, 114, 17-21.	0.8	11
153	Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes. <i>JAMA Oncology</i> , 2016, 2, 1354.	3.4	426
154	Lessons from breast cancer trials of HER2-kinase inhibitors. <i>Lancet Oncology</i> , The, 2016, 17, 267-268.	5.1	3
155	Cancer immunoprevention. <i>Current Opinion in Immunology</i> , 2016, 39, 52-58.	2.4	50
156	Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 91-101.	1.0	26
157	Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 548-556.	1.0	29
158	Prognostic Factors for Breast Cancer: an Immunomorphological Update. <i>Pathology and Oncology Research</i> , 2016, 22, 449-452.	0.9	17
159	The immune microenvironment of breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2016, 29, 249-258.	2.9	119
160	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. <i>Cancer Research</i> , 2016, 76, 264-274.	0.4	21
161	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
162	Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 41-48.	1.6	25
163	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. <i>Human Pathology</i> , 2016, 47, 52-63.	1.1	284
164	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016, 21, 283-291.	1.9	45

#	ARTICLE	IF	CITATIONS
165	Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. <i>Future Oncology</i> , 2016, 12, 1413-1428.	1.1	24
166	Biomarkers for Predicting Response to Anti-HER2 Agents. <i>Advances in Experimental Medicine and Biology</i> , 2016, 882, 155-167.	0.8	5
167	Identification of immune cell infiltration in hematoxylin-eosin stained breast cancer samples: texture-based classification of tissue morphologies. <i>Proceedings of SPIE</i> , 2016, , .	0.8	5
168	New Strategies in Breast Cancer: Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 2105-2110.	3.2	124
169	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2016, 8, 1-13.	0.5	8
170	Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Can We Understand It Better?. <i>Journal of Clinical Oncology</i> , 2016, 34, 521-523.	0.8	6
171	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150.	0.8	683
172	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 487-503.	12.5	43
173	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1223-1230.	0.8	300
174	Breast cancer stem cells phenotype and plasma cell-predominant breast cancer independently indicate poor survival. <i>Pathology Research and Practice</i> , 2016, 212, 294-301.	1.0	20
175	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 2242-2248.	0.7	85
176	Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1029061.	0.3	6
177	Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3249-3259.	3.2	88
178	The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. <i>Oncolmmunology</i> , 2016, 5, e1085148.	2.1	45
179	Long-term survival and stage I breast cancer subtypes. <i>Journal of Cancer Research and Practice</i> , 2016, 3, 1-8.	0.2	13
180	Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1104-1110.	0.7	116
181	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345.	3.2	58
182	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2016, 27, 249-256.	0.6	125

#	ARTICLE	IF	CITATIONS
183	Trabectedin for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 105-115.	1.9	31
184	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 704-713.	3.2	173
185	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
186	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 542-549.	0.8	336
187	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. <i>Tumor Biology</i> , 2016, 37, 4135-4142.	0.8	34
188	Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2016, 18, 497-506.	1.2	98
189	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	3.2	51
190	Enlisting the Immune System to Cure Breast Cancer—A Recipe for Success. <i>JAMA Oncology</i> , 2016, 2, 25.	3.4	7
191	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 56.	3.4	183
192	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. <i>Breast Cancer</i> , 2017, 24, 3-15.	1.3	165
193	Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. <i>Cancer Letters</i> , 2017, 400, 259-266.	3.2	14
194	Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. <i>Cancer Science</i> , 2017, 108, 81-90.	1.7	41
195	Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival. <i>Scientific Reports</i> , 2017, 7, 40177.	1.6	12
197	Breast Cancer Immunology and Immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 1-53.	1.6	47
198	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 21-35.	1.1	102
199	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017, 74, 47-54.	1.3	21
201	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	2.1	146
202	Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. <i>Human Pathology</i> , 2017, 64, 7-12.	1.1	64

#	ARTICLE	IF	CITATIONS
203	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 479-488.	1.1	14
204	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3317-3324.	0.4	117
205	Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1131-1142.	2.0	5
206	The Characteristics of Naive-like T Cells in Tumor-infiltrating Lymphocytes From Human Lung Cancer. <i>Journal of Immunotherapy</i> , 2017, 40, 1-10.	1.2	25
207	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
208	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	3.4	75
209	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. <i>American Journal of Surgical Pathology</i> , 2017, 41, 334-342.	2.1	143
210	Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 409-420.	1.1	58
211	Relationship of the Breast Ductal Carcinoma <i>In Situ</i> Immune Microenvironment with Clinicopathological and Genetic Features. <i>Clinical Cancer Research</i> , 2017, 23, 5210-5217.	3.2	61
212	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. <i>Modern Pathology</i> , 2017, 30, 1204-1212.	2.9	81
213	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 493-511.	1.4	58
214	Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. <i>Annals of Oncology</i> , 2017, 28, 1832-1835.	0.6	36
215	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
216	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
217	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. <i>Annals of Oncology</i> , 2017, 28, 2233-2240.	0.6	75
218	Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. <i>Breast</i> , 2017, 34, 83-88.	0.9	22
219	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 153-164.	0.4	59
220	Clinical utility of gene-expression signatures in early stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 595-610.	12.5	197

#	ARTICLE	IF	CITATIONS
221	Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. <i>Journal of Clinical Pathology</i> , 2017, 70, 860-867.	1.0	47
222	Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	0.8	73
223	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. <i>Clinical Cancer Research</i> , 2017, 23, 4429-4440.	3.2	142
224	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
225	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
226	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017, 49, 141-155.	0.3	112
227	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	0.6	72
228	Correlation between Tumor-Infiltrating Lymphocytes and Pathological Response in Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy in H. Adam Malik General Hospital. <i>Case Reports in Oncology</i> , 2017, 10, 699-705.	0.3	2
229	More T Cells versus Better T Cells in Patients with Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1062-1064.	7.7	6
230	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. <i>Human Pathology</i> , 2017, 69, 110-117.	1.1	81
231	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. <i>ESMO Open</i> , 2017, 2, e000208.	2.0	47
232	Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. <i>Oncology Letters</i> , 2017, 14, 4197-4205.	0.8	23
233	LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. <i>Annals of Oncology</i> , 2017, 28, 2977-2984.	0.6	139
234	The influence of physical activity in the anti-tumor immune response in experimental breast tumor. <i>Immunology Letters</i> , 2017, 190, 148-158.	1.1	27
235	Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures. , 2017, , 259-280.		0
236	Tumour infiltrating lymphocytes are predictors of lymph node metastasis in early gastric cancers. <i>Pathology</i> , 2017, 49, 589-595.	0.3	20
237	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017, 77, 5652-5663.	0.4	90
238	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , 2017, 8, 606.	5.8	89

#	ARTICLE	IF	CITATIONS
239	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
241	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. <i>Modern Pathology</i> , 2017, 30, 1551-1560.	2.9	35
242	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. <i>American Journal of Pathology</i> , 2017, 187, 2185-2198.	1.9	17
243	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. <i>Breast</i> , 2017, 35, 142-150.	0.9	87
244	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, e172085.	3.4	37
245	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
246	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. <i>ESMO Open</i> , 2017, 2, e000150.	2.0	105
247	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
248	Reducing Interstitial Fluid Pressure and Inhibiting Pulmonary Metastasis of Breast Cancer by Gelatin Modified Cationic Lipid Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 29457-29468.	4.0	66
249	PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody. <i>Onc Immunology</i> , 2017, 6, e1353857.	2.1	14
250	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
251	Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. <i>ESMO Open</i> , 2017, 2, e000202.	2.0	10
252	NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 17064.	1.6	67
253	Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 217-226.	0.5	0
255	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 164-171.	1.3	7
256	Premalignant and Pre-invasive Lesions of the Breast. , 2017, , 103-120.		2
257	Expression and Clinical Significance of Herpes Virus Entry Mediator (HVEM) in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 4042-4050.	0.7	30
258	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	0.9	46

#	ARTICLE	IF	CITATIONS
259	Evolution of anti-HER2 therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , 2017, 59, 1-21.	3.4	73
260	Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes. <i>Breast Cancer Research</i> , 2017, 19, 71.	2.2	65
261	Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. <i>BMC Medical Research Methodology</i> , 2017, 17, 83.	1.4	10
262	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
263	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). <i>Breast</i> , 2017, 34, S27-S30.	0.9	107
264	PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. <i>Cell Death and Differentiation</i> , 2017, 24, 1705-1716.	5.0	64
265	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw192.	3.0	296
266	Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers. <i>Breast</i> , 2017, 31, 34-39.	0.9	8
267	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
268	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 602-611.	2.7	76
269	TNF α -Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 636-648.	3.2	74
270	Pretreatment Prognostic Nutritional Index Is an Independent Predictor of Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 100-111.	0.9	28
271	PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. <i>Cancer Research</i> , 2017, 77, 312-319.	0.4	28
272	Optimal duration of adjuvant endocrine therapy: how to apply the newest data. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 679-692.	1.4	10
273	Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. <i>Oncology Letters</i> , 2017, 14, 6421-6432.	0.8	27
274	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 59-104.	0.8	46
275	Regulation of CTL Infiltration Within the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 33-49.	0.8	25
276	Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab. <i>Scientific Reports</i> , 2017, 7, 18027.	1.6	21

#	ARTICLE	IF	CITATIONS
277	Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. <i>BMC Cancer</i> , 2017, 17, 888.	1.1	46
278	DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 3090-3102.	3.9	110
279	Early-Stage Progression of Breast Cancer. , 2017, , .		4
280	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 114156-114172.	0.8	139
281	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
282	Prognostic immune-related gene models for breast cancer: a pooled analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4423-4433.	1.0	10
283	Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1936.	1.8	19
284	Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2321.	1.8	8
285	PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer. <i>Molecules</i> , 2017, 22, 2277.	1.7	12
286	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , 2017, 7, 156.	1.3	87
287	Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-14.	0.9	11
288	Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. <i>Disease Markers</i> , 2017, 2017, 1-14.	0.6	24
289	The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review. <i>Journal of Cancer</i> , 2017, 8, 3838-3848.	1.2	16
290	Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. <i>PLoS ONE</i> , 2017, 12, e0170634.	1.1	69
291	Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. <i>Diagnostic Pathology</i> , 2017, 12, 69.	0.9	25
292	Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. <i>Tropical Medicine and Health</i> , 2017, 45, 19.	1.0	7
293	Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Ecancermedicalscience</i> , 2017, 11, 759.	0.6	21
294	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	0.8	30

#	ARTICLE	IF	CITATIONS
295	Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 65-75.	1.8	8
296	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. Modern Pathology, 2018, 31, 1012-1025.	2.9	25
297	Expression of <scp>MAGE</scp>â€A and <scp>NY</scp>â€1<scp>ESO</scp>â€1 cancer/testis antigens is enriched in tripleâ€negative invasive breast cancers. Histopathology, 2018, 73, 68-80.	1.6	34
298	Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. Clinical Breast Cancer, 2018, 18, 410-417.	1.1	24
299	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications, 2018, 9, 1614.	5.8	76
300	Atezolizumab for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2018, 18, 595-603.	1.4	17
301	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 2018, 19, 22.	1.3	60
302	Poor prognosis in Epsteinâ€Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer, 2018, 21, 925-935.	2.7	13
304	Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Annals of Surgical Oncology, 2018, 25, 937-946.	0.7	37
305	Checkpoint inhibitors in tripleâ€negative breast cancer (TNBC): Where to go from here. Cancer, 2018, 124, 2086-2103.	2.0	141
306	The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Review of Molecular Diagnostics, 2018, 18, 227-243.	1.5	115
307	Immune Checkpoint Blockade for Breast Cancer. Cancer Treatment and Research, 2018, 173, 155-165.	0.2	69
308	Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncology, 2018, 14, 391-407.	1.1	22
309	Annals of Oncology: factors for making a real impact. Annals of Oncology, 2018, 29, 28-29.	0.6	2
310	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clinical and Translational Oncology, 2018, 20, 815-826.	1.2	57
311	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
312	Crosstalk between cancer and the neuro-immune system. Journal of Neuroimmunology, 2018, 315, 15-23.	1.1	48
313	Tumor-infiltrating lymphocytes are associated with β -catenin overexpression in breast cancer. Cancer Biomarkers, 2018, 21, 639-650.	0.8	9

#	ARTICLE	IF	CITATIONS
314	Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 39-54.	1.3	26
315	Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer. <i>Bioscience Reports</i> , 2018, 38, .	1.1	60
316	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. <i>Breast Cancer Research</i> , 2018, 20, 15.	2.2	71
317	The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. <i>Cancer Treatment Reviews</i> , 2018, 67, 34-44.	3.4	71
318	Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities. <i>OncImmunology</i> , 2018, 7, e1466019.	2.1	4
319	Checkpoint Inhibitors in the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2018, 20, 51.	1.8	10
321	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.	3.2	65
322	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 4899.	1.6	91
323	Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 135-145.	1.1	27
324	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	1.1	16
325	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , 2018, 25, 34-42.	1.3	88
326	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	0.9	108
327	The emerging world of breast cancer immunotherapy. <i>Breast</i> , 2018, 37, 200-206.	0.9	39
328	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018, 29, 170-177.	0.6	84
329	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
330	Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. <i>Modern Pathology</i> , 2018, 31, 288-298.	2.9	38
331	Prognostic and predictive biomarkers in breast cancer: Past, present and future. <i>Seminars in Cancer Biology</i> , 2018, 52, 56-73.	4.3	284
332	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 39-47.	1.1	28

#	ARTICLE	IF	CITATIONS
333	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 89-99.	1.1	74
334	Triple negative breast cancer – prognostic role of immune-related factors: a systematic review. <i>Acta Oncologica</i> , 2018, 57, 74-82.	0.8	93
335	Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. <i>Acta Oncologica</i> , 2018, 57, 90-94.	0.8	35
336	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 337-348.	1.1	6
337	Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer. <i>Breast Cancer</i> , 2018, 25, 268-274.	1.3	12
338	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
339	Breast cancer genomics and immuno-oncological markers to guide immune therapies. <i>Seminars in Cancer Biology</i> , 2018, 52, 178-188.	4.3	111
340	Single-cell heterogeneity in ductal carcinoma in situ of breast. <i>Modern Pathology</i> , 2018, 31, 406-417.	2.9	41
341	Immunomodulatory effects of a bioactive fraction of <i>Strobilanthes crispus</i> in NMU-induced rat mammary tumor model. <i>Journal of Ethnopharmacology</i> , 2018, 213, 31-37.	2.0	16
342	Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 166-175.	3.0	122
344	Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. <i>Oncology Letters</i> , 2019, 17, 2177-2186.	0.8	20
346	Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy. <i>Targeted Oncology</i> , 2018, 13, 757-767.	1.7	15
347	Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 307.	1.8	16
348	Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC). <i>Current Breast Cancer Reports</i> , 2018, 10, 282-288.	0.5	1
349	The clinical promise of immunotherapy in triple-negative breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6823-6833.	0.9	113
350	Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. <i>ACS Nano</i> , 2018, 12, 11740-11755.	7.3	176
351	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. <i>Frontiers in Oncology</i> , 2018, 8, 609.	1.3	17
352	Distribution of CD4 ⁺ and CD8 ⁺ exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6139-6145.	1.0	6

#	ARTICLE	IF	CITATIONS
353	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018, 7, 5066-5082.	1.3	12
354	Tumor microenvironmental factors have prognostic significances in advanced gastric cancer. <i>Apmis</i> , 2018, 126, 814-821.	0.9	11
355	Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. <i>ESMO Open</i> , 2018, 3, e000305.	2.0	34
356	Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2018, 16, 4984-4996.	0.8	27
357	Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). <i>Journal of Hematology and Oncology</i> , 2018, 11, 124.	6.9	17
358	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , 2018, 13, e0204513.	1.1	34
360	Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 16008.	1.6	20
361	TIM-3 expression in breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1502128.	2.1	42
362	Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 101.	2.2	44
363	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. <i>Breast Cancer Research</i> , 2018, 20, 108.	2.2	81
364	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
365	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 52-60.	1.3	16
366	Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. <i>Diagnostic Pathology</i> , 2018, 13, 66.	0.9	33
367	<i>FcR3A</i> -158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 45.	0.8	0
368	Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. <i>Nature Communications</i> , 2018, 9, 3588.	5.8	342
369	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62.	2.2	54
370	Checkpoint blockade in the treatment of breast cancer: current status and future directions. <i>British Journal of Cancer</i> , 2018, 119, 4-11.	2.9	82
371	Hot Spot and Whole-Tumor Enumeration of CD8+ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 451-458.e1.	1.1	25

#	ARTICLE	IF	CITATIONS
372	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	2.0	112
373	Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 1-9.	1.1	37
374	<i>Molecular Biology of Breast Cancer.</i> , 2018, , 569-588.		6
375	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 65-74.	1.1	11
376	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 629-649.	1.1	31
377	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. <i>Histopathology</i> , 2018, 73, 887-896.	1.6	62
378	IFN β -induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody. <i>Clinical Cancer Research</i> , 2018, 24, 6447-6458.	3.2	32
379	Mechanisms of immune evasion in breast cancer. <i>BMC Cancer</i> , 2018, 18, 556.	1.1	180
380	Genetic Markers in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e841-e850.	1.1	148
381	Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2018, 150, 441-450.	0.4	28
382	Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality. <i>Cancer Management and Research</i> , 2018, Volume 10, 1365-1375.	0.9	17
383	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1209.	2.2	114
384	Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer. <i>Cancers</i> , 2018, 10, 205.	1.7	49
385	Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. <i>Journal of Controlled Release</i> , 2018, 285, 23-34.	4.8	44
386	Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 563.	1.8	44
387	Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2852-2857.	0.7	15
388	Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 56.	1.1	63
389	Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 320.	1.1	22

#	ARTICLE	IF	CITATIONS
390	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. <i>Scientific Reports</i> , 2018, 8, 7205.	1.6	71
391	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1490854.	2.1	200
392	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
393	Is there a role for immunotherapy in HER2-positive breast cancer?. <i>Npj Breast Cancer</i> , 2018, 4, 21.	2.3	19
394	Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 77-79.	0.6	18
395	Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2018, 29, 1741-1747.	0.6	56
396	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
397	Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer. <i>Human Pathology</i> , 2018, 80, 47-54.	1.1	18
398	New horizons in breast cancer: the promise of immunotherapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 117-125.	1.2	21
399	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 69-77.	3.0	60
400	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149
401	The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 709-725.	1.4	14
402	Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention. <i>Trends in Molecular Medicine</i> , 2019, 25, 866-881.	3.5	54
403	Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group. <i>Cancer Management and Research</i> , 2019, Volume 11, 6815-6827.	0.9	14
404	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). <i>Oncologist</i> , 2019, 24, 1439-1445.	1.9	40
405	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. <i>Oncolmmunology</i> , 2019, 8, e1629780.	2.1	34
406	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
407	Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 10961.	1.6	63

#	ARTICLE	IF	CITATIONS
408	Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS). <i>Annals of Surgical Oncology</i> , 2019, 26, 3337-3343.	0.7	16
409	Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. <i>Cancers</i> , 2019, 11, 911.	1.7	40
410	Aggregable Nanoparticles-Enabled Chemotherapy and Autophagy Inhibition Combined with Anti-PD-L1 Antibody for Improved Glioma Treatment. <i>Nano Letters</i> , 2019, 19, 8318-8332.	4.5	142
411	PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1566.	1.7	7
412	Preparation of Immunotherapy Liposomal-Loaded Thermal-Responsive Hydrogel Carrier in the Local Treatment of Breast Cancer. <i>Polymers</i> , 2019, 11, 1592.	2.0	14
413	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6731-6741.	3.2	53
414	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Oncolmmunology</i> , 2019, 8, e1674605.	2.1	59
415	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
416	Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 947-961.	2.7	24
417	Emerging Novel Therapeutics in Triple-Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 377-399.	0.8	23
418	BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. <i>Cancer Letters</i> , 2019, 465, 45-58.	3.2	36
419	Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 97-106.	1.3	10
420	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019, 11, 1325.	1.7	7
421	Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model. <i>International Immunopharmacology</i> , 2019, 76, 105864.	1.7	13
422	Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3105-3114.	1.2	63
423	Association Between Circulating Lymphocyte Populations and Outcome After Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 896.	1.3	23
424	Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. <i>Oncology Letters</i> , 2019, 17, 4557-4565.	0.8	16
425	The Use of Immunotherapy to Treat Metastatic Breast Cancer. <i>Current Medicinal Chemistry</i> , 2019, 26, 941-962.	1.2	14

#	ARTICLE	IF	CITATIONS
426	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 53-69.	1.0	63
427	Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 963-968.	0.5	25
428	Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 291-299.	0.9	23
429	Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133.		32
430	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 1208-1227.	7.7	81
431	Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 605-617.	0.8	28
432	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	0.6	18
433	Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 541.	1.1	16
434	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 3111-3119.	0.5	12
435	Prognostic role of immune infiltrates in breast ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 17-27.	1.1	40
436	FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, 1289-1297.	0.6	97
437	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 589-601.	1.1	8
438	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. <i>Scientific Reports</i> , 2019, 9, 8572.	1.6	36
439	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node- positive study. <i>European Journal of Cancer</i> , 2019, 114, 76-88.	1.3	37
440	Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines. <i>Viruses</i> , 2019, 11, 434.	1.5	4
441	The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. <i>Annals of Diagnostic Pathology</i> , 2019, 40, 143-151.	0.6	33
442	Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. <i>Oncology Letters</i> , 2019, 17, 2647-2656.	0.8	56
443	Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1. <i>Breast Disease</i> , 2019, 38, 57-65.	0.4	1

#	ARTICLE	IF	CITATIONS
444	BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. <i>BMC Cancer</i> , 2019, 19, 387.	1.1	17
445	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 867-871.	3.0	41
446	Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5002-5014.	3.2	269
447	A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis. <i>Anticancer Research</i> , 2019, 39, 1217-1232.	0.5	21
448	Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. <i>Scientific Reports</i> , 2019, 9, 3461.	1.6	11
449	Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer</i> , 2019, 26, 573-580.	1.3	12
450	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
451	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. , 2019, 7, 90.		80
452	Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. <i>Cancer Biology and Therapy</i> , 2019, 20, 1105-1112.	1.5	22
453	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
454	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1179-1187.	0.8	41
455	Harnessing the Immune System in HER2+ Disease. , 2019, , 213-230.		0
456	Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. <i>BMC Cancer</i> , 2019, 19, 120.	1.1	37
457	The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. <i>Annals of Oncology</i> , 2019, 30, 575-581.	0.6	18
458	Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. <i>Clinical Cancer Research</i> , 2019, 25, 4422-4430.	3.2	6
459	A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 149-162.	1.0	8
460	Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 343-356.	2.1	23
461	Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. <i>Journal of Breast Cancer</i> , 2019, 22, 497.	0.8	20

#	ARTICLE	IF	CITATIONS
463	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. <i>Current Breast Cancer Reports</i> , 2019, 11, 248-258.	0.5	2
464	Targeted Therapies for Triple-Negative Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 82.	1.3	237
465	Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer. <i>Journal of Cancer</i> , 2019, 10, 6175-6184.	1.2	106
466	Immunotherapy in Triple-Negative Breast Cancer: Present and Future. <i>Current Breast Cancer Reports</i> , 2019, 11, 259-271.	0.5	22
467	Recent Developments in HER2-Directed Therapy in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 311-325.	0.5	0
468	Risk stratification according to stage and pathology. <i>Breast</i> , 2019, 48, S23-S25.	0.9	2
469	Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. <i>Advances in Anatomic Pathology</i> , 2019, 26, 221-234.	2.4	22
470	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.	2.1	5
471	Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 167-177.	1.1	18
472	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
473	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
475	Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2019, 10, 219-225.	0.8	7
476	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. <i>Breast Care</i> , 2019, 14, 53-59.	0.8	13
477	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
478	Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2. <i>Cancer Letters</i> , 2019, 443, 157-166.	3.2	3
479	HER2-Positive Early Breast Cancer. , 2019, , 371-382.		0
480	Recent advances in breast cancer research impacting clinical diagnostic practice. <i>Journal of Pathology</i> , 2019, 247, 552-562.	2.1	24
481	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	1.1	3

#	ARTICLE	IF	CITATIONS
482	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 418-423.	0.6	66
483	Survival after a cancer diagnosis among solid organ transplant recipients in the United States. <i>Cancer</i> , 2019, 125, 933-942.	2.0	67
484	Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer. <i>Cancer Medicine</i> , 2019, 8, 492-500.	1.3	25
485	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
486	Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 29-42.	1.1	11
487	Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results. <i>Human Pathology</i> , 2019, 85, 27-32.	1.1	11
488	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 255-266.	1.1	96
489	Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. <i>Journal of Clinical Pathology</i> , 2019, 72, 157-164.	1.0	53
490	NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. <i>Clinical Cancer Research</i> , 2019, 25, 1535-1545.	3.2	86
491	Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. <i>Head and Neck</i> , 2019, 41, 1237-1245.	0.9	5
492	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
493	Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy. <i>Pathology and Oncology Research</i> , 2019, 25, 1341-1347.	0.9	0
494	Correlation between magnetic resonance imaging and the level of tumor-infiltrating lymphocytes in patients with estrogen receptor-negative HER2-positive breast cancer. <i>Acta Radiologica</i> , 2020, 61, 3-10.	0.5	10
495	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. <i>Oncogene</i> , 2020, 39, 50-63.	2.6	43
496	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	3.2	70
497	Reactive stroma and trastuzumab resistance in HER2- ϵ positive early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 266-276.	2.3	13
498	AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 18.	1.1	19
499	Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 701-709.	1.4	8

#	ARTICLE	IF	CITATIONS
500	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. <i>Translational Oncology</i> , 2020, 13, 186-192.	1.7	6
501	Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 767-775.	0.6	5
502	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	1.7	52
503	Correlation between 18F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. <i>European Journal of Radiology</i> , 2020, 123, 108773.	1.2	26
504	Immune stromal features in cervical squamous cell carcinoma are prognostic factors for distant metastasis: A retrospective study. <i>Pathology Research and Practice</i> , 2020, 216, 152751.	1.0	6
505	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	3.2	21
506	Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells. <i>Apmis</i> , 2020, 128, 260-269.	0.9	6
507	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. <i>Cytotherapy</i> , 2020, 22, 780-791.	0.3	9
508	CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6968.	1.8	118
509	Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 3038.	1.7	66
510	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
511	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	0.5	1
512	Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway. , 2020, 8, e000761.		10
513	Intratumoral administration of the Toll-like receptor 7/8 agonist 3M052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1177.	1.7	22
514	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020, 80, 1811-1830.	4.9	23
515	Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer. <i>Annals of Diagnostic Pathology</i> , 2020, 49, 151634.	0.6	13
516	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 76.	2.2	41
517	Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3584.	5.8	115

#	ARTICLE	IF	CITATIONS
518	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 28.	2.3	25
519	Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 1150.	1.1	65
520	Biomarkers in Her2- Positive Disease. <i>Breast Care</i> , 2020, 15, 586-593.	0.8	8
521	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 3529.	1.7	60
522	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 575978.	1.3	7
523	Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 84, 310-328.	4.3	34
524	Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. , 2020, 8, e000334.		21
525	The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. <i>Frontiers in Immunology</i> , 2020, 11, 1680.	2.2	194
526	Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 599-606.	1.1	11
527	PD-1/PD-L1 axis importance and tumor microenvironment immune cells. <i>Life Sciences</i> , 2020, 259, 118297.	2.0	26
528	Innovative approaches to immunotherapy in breast cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4536-4540.	0.6	4
529	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. <i>British Journal of Cancer</i> , 2020, 123, 1665-1672.	2.9	26
530	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. <i>In Vivo</i> , 2020, 34, 2641-2646.	0.6	15
531	Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis. <i>BMC Women's Health</i> , 2020, 20, 194.	0.8	17
532	Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial. <i>Cancer</i> , 2020, 126, 4859-4866.	2.0	4
533	Genomic Mapping Identifies Mutations in RYR2 and AHNK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. <i>Cancers</i> , 2020, 12, 2243.	1.7	22
534	Immune parameters associated with survival in metaplastic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 92.	2.2	23
535	Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9460.	1.8	7

#	ARTICLE	IF	CITATIONS
536	Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	71
537	Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice. <i>Scientific Reports</i> , 2020, 10, 20100.	1.6	11
538	Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8238.	1.8	12
539	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. <i>Cancer Prevention Research</i> , 2020, 13, 901-910.	0.7	10
540	An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. <i>Theranostics</i> , 2020, 10, 11938-11949.	4.6	85
541	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. <i>BMC Cancer</i> , 2020, 20, 445.	1.1	11
542	Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. <i>PLoS ONE</i> , 2020, 15, e0233037.	1.1	17
543	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2198-2207.	2.9	21
544	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
545	Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 480-490.	1.0	52
546	Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 3345-3354.	0.5	11
547	Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 341-357.	1.0	7
548	Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4438.	1.8	9
549	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	1.7	78
550	Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer. <i>Targeted Oncology</i> , 2020, 15, 415-428.	1.7	22
551	HER family in cancer progression: From discovery to 2020 and beyond. <i>Advances in Cancer Research</i> , 2020, 147, 109-160.	1.9	27
552	Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features. <i>Breast Care</i> , 2020, 15, 208-216.	0.8	6
553	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. <i>Pathology</i> , 2020, 52, 515-521.	0.3	5

#	ARTICLE	IF	CITATIONS
554	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 122, 1496-1506.	2.9	26
555	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. <i>PLoS ONE</i> , 2020, 15, e0229955.	1.1	20
556	Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. <i>Chinese Medical Journal</i> , 2020, 133, 552-560.	0.9	11
557	Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102927.	2.0	15
558	Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment. <i>Scientific Reports</i> , 2020, 10, 3933.	1.6	6
559	Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. <i>Anticancer Research</i> , 2020, 40, 1487-1494.	0.5	16
560	NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. <i>Nature Communications</i> , 2020, 11, 1669.	5.8	93
561	Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. <i>Cancers</i> , 2020, 12, 636.	1.7	40
562	Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2020, 20, 179.	1.1	119
563	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
564	Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer. <i>BMC Cancer</i> , 2020, 20, 598.	1.1	19
565	Development and verification of a personalized immune prognostic feature in breast cancer. <i>Experimental Biology and Medicine</i> , 2020, 245, 1242-1253.	1.1	2
566	The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. <i>Frontiers in Oncology</i> , 2020, 10, 1022.	1.3	31
567	CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 767-775.	1.4	45
568	Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 584.	1.1	15
569	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 347-354.	1.1	59
570	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
571	Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 369-377.	1.1	33

#	ARTICLE	IF	CITATIONS
572	Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. <i>Pharmacological Research</i> , 2020, 153, 104683.	3.1	269
573	Invasive breast cancer: Current perspectives and emerging views. <i>Pathology International</i> , 2020, 70, 242-252.	0.6	11
574	Interfering MSN-NONO complexâ€activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. <i>Science Advances</i> , 2020, 6, eaaw9960.	4.7	26
575	Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 799-811.	2.0	10
576	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	3.4	92
577	Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. <i>European Journal of Cancer</i> , 2020, 127, 236-239.	1.3	3
578	Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9 ⁺ T cells. <i>Science Advances</i> , 2020, 6, eaax4690.	4.7	51
579	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. <i>European Journal of Cancer</i> , 2020, 127, 240-250.	1.3	21
580	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1486.	1.3	20
581	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 331-338.	1.1	25
582	Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. <i>American Journal of Pathology</i> , 2020, 190, 1491-1504.	1.9	66
583	Low expression of RGL4 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients. <i>International Immunopharmacology</i> , 2020, 83, 106454.	1.7	18
584	Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. <i>Breast Disease</i> , 2020, 39, 61-69.	0.4	15
585	Intratumoral CD103â€positive tumourâ€infiltrating lymphocytes are associated with favourable prognosis in patients with tripleâ€negative breast cancer. <i>Histopathology</i> , 2020, 77, 560-569.	1.6	15
586	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. <i>Chinese Medical Journal</i> , 2020, 133, 853-862.	0.9	21
587	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2020, 9, 66.	2.5	16
588	Prediction model of the response to neoadjuvant chemotherapy in breast cancers by a Naive Bayes algorithm. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 192, 105458.	2.6	17
589	Oncolytic vesicular stomatitis virusâ€based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 ⁺ T-cell functionality. , 2020, 8, e000465.		28

#	ARTICLE	IF	CITATIONS
590	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. <i>Pathobiology</i> , 2020, 87, 125-142.	1.9	49
591	Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 1883-1890.	0.5	23
592	T-cell-based breast cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 72, 90-101.	4.3	21
593	Correlations between CD4 ⁺ FoxP3 ⁺ Treg and expression of FoxM1 and Ki67 in gastric cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e63-e69.	0.7	7
594	Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. <i>Clinical Cancer Research</i> , 2021, 27, 749-758.	3.2	10
595	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
596	Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'Évaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit. <i>Plastic Surgery</i> , 2021, 29, 4-9.	0.4	0
597	Peripheral Blood Leukocytes and Platelets Serve as Prognostic Factors in Breast Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 167-173.	0.7	6
598	The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. <i>Bioactive Materials</i> , 2021, 6, 697-711.	8.6	10
599	Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis. <i>Surgery Today</i> , 2021, 51, 595-604.	0.7	1
600	Tumor-Infiltrating Lymphocytes in Low-Risk Patients With Breast Cancer Treated With Single-Dose Preoperative Partial Breast Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1325-1331.	0.4	11
601	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. <i>Science China Life Sciences</i> , 2021, 64, 372-388.	2.3	26
602	The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 63-72.	1.1	30
603	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89.	4.3	87
604	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	1.1	19
605	Modulation of Immune System – Strategy in the Treatment of Breast Cancer. <i>In Vivo</i> , 2021, 35, 2889-2894.	0.6	3
606	MPA/DMBA-driven mammary carcinomas. <i>Methods in Cell Biology</i> , 2021, 163, 1-19.	0.5	5
607	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	0.8	4

#	ARTICLE	IF	CITATIONS
608	KCTD12 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Translational Cancer Research</i> , 2021, 10, 261-272.	0.4	1
609	Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 636.	1.8	29
610	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. <i>Cells</i> , 2021, 10, 223.	1.8	115
611	Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1005-1016.	3.0	171
612	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	1.3	100
613	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 4691.	1.6	53
614	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	0.8	6
615	Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers. <i>Frontiers in Genetics</i> , 2021, 12, 616469.	1.1	12
616	Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 45-55.	1.1	8
617	The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia. <i>Case Reports in Oncology</i> , 2021, 14, 347-351.	0.3	0
618	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. , 2021, 9, e002022.		40
619	Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment. <i>Current Oncology Reports</i> , 2021, 23, 55.	1.8	12
620	Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis. <i>Cancer Management and Research</i> , 2021, Volume 13, 2095-2104.	0.9	6
621	The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)â€”Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. <i>Cancers</i> , 2021, 13, 1964.	1.7	50
622	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
623	Immune-related biomarkers in triple-negative breast cancer. <i>Breast Cancer</i> , 2021, 28, 792-805.	1.3	24
624	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. <i>Nature Cancer</i> , 2021, 2, 400-413.	5.7	41
625	Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics. <i>Breast</i> , 2021, 56, 78-87.	0.9	18

#	ARTICLE	IF	CITATIONS
626	Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment. <i>Gland Surgery</i> , 2021, 10, 1300-1314.	0.5	4
627	Prognostic Significance and Tumor Immune Microenvironment Heterogeneity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 657547.	1.8	57
628	Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. <i>Cancers</i> , 2021, 13, 1655.	1.7	6
629	The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 3403-3412.	1.3	3
630	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. <i>European Journal of Cancer</i> , 2021, 148, 134-145.	1.3	10
631	A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2401.	1.7	16
632	Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 904-909.	1.5	1
633	Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer (literature) Tj ETQq1 1 0.784314,rgBT /Overlock 10	0.1	0
634	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	2.2	68
635	Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. <i>Cancer Investigation</i> , 2021, 39, 466-472.	0.6	0
636	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
637	Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. <i>Cancer Medicine</i> , 2021, 10, 4790-4795.	1.3	6
638	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
639	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 4992-5001.	2.6	68
640	The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type. <i>Breast Disease</i> , 2021, 40, S9-S14.	0.4	0
641	Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring 1cm. <i>Scientific Reports</i> , 2021, 11, 12046.	1.6	5
642	Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 62-71.	0.6	20
643	Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. <i>Cells</i> , 2021, 10, 1429.	1.8	5

#	ARTICLE	IF	CITATIONS
644	Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival. <i>Scientific Reports</i> , 2021, 11, 12541.	1.6	25
645	Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 668610.	1.3	4
646	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5557-5565.	3.2	26
647	Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 310.	1.8	21
648	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.4	40
649	GMFG Has Potential to Be a Novel Prognostic Marker and Related to Immune Infiltrates in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 629633.	1.3	5
650	Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 3626.	1.7	9
651	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800.	0.9	25
652	Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement. <i>Plastic and Reconstructive Surgery</i> , 2021, 148, 287-298.	0.7	4
653	Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression. <i>Molecular Oncology</i> , 2022, 16, 88-103.	2.1	18
654	ChrNet: A re-trainable chromosome-based 1D convolutional neural network for predicting immune cell types. <i>Genomics</i> , 2021, 113, 2023-2031.	1.3	5
655	PI3KÎ± Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 845-858.	0.4	15
656	Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6788.	1.3	5
657	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	2.9	14
658	BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Academic Radiology</i> , 2022, 29, S35-S41.	1.3	7
659	Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8377.	1.8	1
660	Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 772-784.	1.9	17
661	The characteristics and novel clinical implications of CD4+CXCR5+Foxp3+ follicular regulatory T cells in breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1332-1332.	0.7	3

#	ARTICLE	IF	CITATIONS
662	Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188587.	3.3	32
663	A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer. <i>EBioMedicine</i> , 2021, 70, 103492.	2.7	31
664	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
665	Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. <i>Biology</i> , 2021, 10, 768.	1.3	1
666	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	0.6	393
667	Comprehensive Analysis of RUNX and TGF- β 2 Mediated Regulation of Immune Cell Infiltration in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 730380.	1.8	12
668	Anticancer Properties of <i>Strobilanthes crispus</i> : A Review. <i>Processes</i> , 2021, 9, 1370.	1.3	6
669	An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 704655.	2.2	5
670	A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. <i>Aging</i> , 2021, 13, 19486-19509.	1.4	28
671	HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes. <i>American Journal of Roentgenology</i> , 2022, 218, 258-269.	1.0	15
672	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4410.	1.7	8
673	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 128.	2.3	2
674	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91
675	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 599-606.	1.1	11
676	Single-cell profiling defines the prognostic benefit of CD39 ^{high} tissue resident memory CD8 ⁺ T cells in luminal-like breast cancer. <i>Communications Biology</i> , 2021, 4, 1117.	2.0	11
677	Prognostic Effect of Microenvironment Phenotype in Triple-Negative Breast Cancer: Biomarker Analysis of a Prospective Trial. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 752154.	1.6	2
678	Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 675533.	1.3	5
679	Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 582664.	1.3	11

#	ARTICLE	IF	CITATIONS
680	Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice. <i>Cancers</i> , 2021, 13, 4883.	1.7	15
681	Dissecting the biological heterogeneity of HER2-positive breast cancer. <i>Breast</i> , 2021, 59, 339-350.	0.9	41
682	Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model. <i>International Immunopharmacology</i> , 2021, 99, 107924.	1.7	13
683	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	70
684	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2021, 10, 1929724.	2.1	22
685	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. <i>Oncolmmunology</i> , 2021, 10, 1924492.	2.1	8
686	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
687	Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. <i>Breast Cancer</i> , 2020, 27, 519-526.	1.3	6
688	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018, 24, 986-993.	15.2	689
691	Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. , 2020, 8, e000696.		88
692	Modeling Immune-Mediated Activations and Interactions in Breast Cancer Progression. <i>International Journal of Systems Science and Applied Mathematics</i> , 2019, 4, 1.	0.2	1
693	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	182
694	Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. <i>Breast Cancer Research</i> , 2020, 22, 140.	2.2	25
695	Identification of Genes with Prognostic Value in the Breast Cancer Microenvironment Using Bioinformatics Analysis. <i>Medical Science Monitor</i> , 2020, 26, e920212.	0.5	9
696	Triple-negative breast cancer: recent treatment advances. <i>F1000Research</i> , 2019, 8, 1342.	0.8	152
697	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152500.	1.1	219
698	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. <i>PLoS ONE</i> , 2017, 12, e0168669.	1.1	111
699	Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?. <i>Acta Facultatis Medicae Naissensis</i> , 2016, 33, 237-246.	0.1	1

#	ARTICLE	IF	CITATIONS
700	Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 333-351.	0.2	44
701	Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer. <i>Aging</i> , 2020, 12, 17305-17327.	1.4	14
702	Construction and validation of an immunity-related prognostic signature for breast cancer. <i>Aging</i> , 2020, 12, 21597-21612.	1.4	9
703	Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 44395-44405.	0.8	25
704	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	0.8	44
705	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016, 7, 63424-63436.	0.8	12
706	IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). <i>Oncotarget</i> , 2017, 8, 2731-2744.	0.8	21
707	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 15584-15592.	0.8	101
708	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. <i>Oncotarget</i> , 2017, 8, 15610-15620.	0.8	21
709	The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. <i>Oncotarget</i> , 2018, 9, 6201-6212.	0.8	33
710	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
711	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. <i>Oncotarget</i> , 2015, 6, 28173-28182.	0.8	34
712	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	0.8	14
713	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
714	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	0.8	54
715	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. <i>Oncotarget</i> , 2016, 7, 255-265.	0.8	39
716	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. <i>Oncotarget</i> , 2016, 7, 64431-64446.	0.8	161
717	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33

#	ARTICLE	IF	CITATIONS
718	MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. , 2020, 3, 603-612.		15
719	Triple negative breast cancer: special histological types and emerging therapeutic methods. Cancer Biology and Medicine, 2020, 17, 293-306.	1.4	50
720	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
721	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets, 2015, 15, 652-664.	0.8	33
722	Immune Blockade Inhibition in Breast Cancer. Anticancer Research, 2016, 36, 5607-5622.	0.5	37
723	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. Anticancer Research, 2017, 37, 2334.	0.5	10
724	Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. , 2017, 37, 5623-5630.		5
725	Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes. Anticancer Research, 2018, 38, 2311-2321.	0.5	37
726	Tumor-Associated Neutrophils in Breast Cancer Subtypes. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2689-2693.	0.5	31
728	TIME Is a Great Healerâ€”Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes. Cells, 2021, 10, 11.	1.8	13
729	The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. Journal of Cancer Research and Therapeutics, 2018, 14, 619.	0.3	5
730	Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. Journal of Pathology and Translational Medicine, 2015, 49, 355-363.	0.4	41
731	Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study. Cancer Research and Treatment, 2019, 51, 1336-1346.	1.3	11
732	Therapeutic strategies to reverse immunosuppressive breast cancer microenvironment. Oncology Discovery, 2016, 4, 1.	0.5	2
733	Prognostic value of tumorâ€™infiltrating lymphocytes in estrogen receptorâ€™positive and human epidermal growth factor receptor 2â€™negative breast cancer. Molecular and Clinical Oncology, 2021, 15, 252.	0.4	10
734	Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics, 2021, 113, 4088-4097.	1.3	8
735	Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression. Npj Breast Cancer, 2021, 7, 136.	2.3	20
736	MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis. Medical Science Monitor, 2022, 27, e934597.	0.5	5

#	ARTICLE	IF	CITATIONS
737	Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 714550.	1.3	3
738	Construction and Identification of a Novel 5-Gene Signature for Predicting the Prognosis in Breast Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 669931.	1.2	10
739	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 39-49.	1.1	11
740	Neoadjuvant <i>In Situ</i> Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors. <i>Cancer Research</i> , 2021, 81, 6183-6195.	0.4	9
741	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 137-145.	1.1	0
742	VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients. <i>Future Oncology</i> , 2021, 17, 4057-4069.	1.1	8
743	A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). <i>European Journal of Cancer</i> , 2021, 158, 169-180.	1.3	9
744	The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients. <i>Journal of Cancer Science & Therapy</i> , 2016, 08, .	1.7	0
745	A Case of Primary Breast Cancer that Developed 20 Years after Living Renal Transplantation. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2016, 77, 1902-1906.	0.0	0
746	Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer. , 2016, , 167-186.		0
747	Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321.		0
748	Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298.		0
749	Définition du pronostic des cancers du sein aujourd'hui: intégration de l'anatomie et de la biologie. , 2016, , 189-195.		0
750	Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016, 02, .	0.1	0
751	Human Epidermal Growth Factor Receptor 2 (HER2): Translating the Lab to the Clinic. , 2016, , 59-70.		0
752	Adjuvant Therapy for HER2-Positive Early Breast Cancer. , 2016, , 189-203.		0
753	Molecular Classification of Breast Cancer. , 2016, , 203-219.		2
754	USING OF BINOMIAL METHOD FOR THE PURPOSE OF DETERMINATION OF CONFIDENCE INTERVALS FOR PREDICTION OF INVASIVE DUCTAL BREAST CARCINOMA METASTASES. <i>EUREKA Health Sciences</i> , 2016, 2, 24-29.	0.1	0

#	ARTICLE	IF	CITATIONS
756	Tumor infiltrating lymphocytes: biological essence and clinical significance in breast cancer. Russian Journal of Oncology, 2016, 21, 92-100.	0.1	2
758	Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235.	0.5	0
759	BET Bromodomain Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-negative Breast Cancer and Elicits Anti-tumor Immune Response. SSRN Electronic Journal, 0, , .	0.4	1
760	Prognostic and Predictive Factors in Breast Carcinoma. , 2018, , 327-356.		1
763	Preoperative Therapy for Operable Breast Cancer. , 2019, , 223-238.		0
764	Adjuvant Therapy for HER-2-Positive Early Breast Cancer. , 2019, , 173-185.		0
765	PROGNOSIS OF NEOADJUVANT CHEMOTHERAPY EFFICACY WITH IMMUNOBIOLOGIC TUMOR MARKERS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER. Likars'ka Sprava, 2019, , 46-54.	0.2	0
766	Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer. Opuholi Zenskoj Reproktivnoij Sistemy, 2019, 15, 10-29.	0.1	3
767	<p>Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes</p>. Cancer Management and Research, 2020, Volume 12, 3145-3153.	0.9	2
768	Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer. The Journal of Breast Health, 2020, 16, 276-281.	0.4	5
769	Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research, 2021, 23, 99.	2.2	23
770	A Case of Breast Cancer Completely Vanished after Biopsy with Vacuum-assisted Breast Biopsy Device. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 41-47.	0.0	0
771	Reporting Core Biopsies: Lesions That Are Highly Suspicious of Malignancy (B4) or Definitely Malignant (B5). In Clinical Practice, 2020, , 95-219.	0.1	0
773	Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs). Journal of Cancer Therapy, 2020, 11, 206-219.	0.1	1
774	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.2	3
776	Prognostic inflammatory markers in metastatic renal cell carcinoma: Neutrophil-to-lymphocyte ratio and prognostic nutritional index. Medical Science and Discovery, 2020, 7, 459-465.	0.1	0
777	Ultrasonography Combined With Contrast-enhanced Ultrasonography Can Predict Lymphocyte-predominant Breast Cancer. Cancer Diagnosis & Prognosis, 2021, 1, 309-316.	0.3	2
778	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers, 2021, 13, 5501.	1.7	10

#	ARTICLE	IF	CITATIONS
780	Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773078.	1.3	9
781	Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naïve and chemotherapy-treated patients with invasive breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 1435-1447.	0.0	6
782	Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. <i>Current Trends in Immunology</i> , 2016, 17, 95-115.	4.0	16
783	Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. <i>Indian Journal of Medical Research</i> , 2017, 146, 563-571.	0.4	3
784	Leveraging Clinical Time-Series Data for Prediction: A Cautionary Tale. <i>AMIA ... Annual Symposium proceedings</i> , 2017, 2017, 1571-1580.	0.2	7
785	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. <i>Oncology Letters</i> , 2021, 21, 36.	0.8	4
786	A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 3611-3627.	1.4	4
787	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 3628-3644.	1.4	3
788	Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. <i>Modern Pathology</i> , 2022, 35, 601-608.	2.9	10
789	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. <i>Cancers</i> , 2021, 13, 5999.	1.7	6
790	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 766248.	1.3	7
791	Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 385-395.	1.4	5
792	Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 774088.	1.3	7
793	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	1.3	49
794	Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate. <i>Cancers</i> , 2021, 13, 5917.	1.7	4
795	Interferon Signaling in Estrogen Receptor-“positive Breast Cancer: A Revitalized Topic. <i>Endocrinology</i> , 2022, 163, .	1.4	16
796	A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer. <i>Translational Cancer Research</i> , 2021, 11, 0-0.	0.4	3
797	The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 1-17.	0.9	38

#	ARTICLE	IF	CITATIONS
798	Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women. <i>Journal of Clinical Medicine</i> , 2022, 11, 283.	1.0	2
799	Breast Cancer Immunotherapy: From Biology to Current Clinical Applications. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 113-124.	3.0	2
800	CD204 ⁺ positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand ¹ expression. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	5
801	Prognostic Value of Metabolic, Volumetric and Textural Parameters of Baseline [18F]FDG PET/CT in Early Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 637.	1.7	17
802	Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 283-293.	0.9	1
803	Mapping Intellectual Structures and Research Hotspots of Triple Negative Breast Cancer: A Bibliometric Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 689553.	1.3	17
804	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
805	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 451.	1.7	14
806	The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 706606.	1.3	9
807	Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 2914-2925.	0.7	16
808	Perspectives on the role of breast cancer susceptibility gene in breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 495-511.	1.0	1
809	Identification and Characterization of Immunogene-Related Alternative Splicing Patterns and Tumor Microenvironment Infiltration Patterns in Breast Cancer. <i>Cancers</i> , 2022, 14, 595.	1.7	2
810	Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response. <i>Future Oncology</i> , 2022, 18, 1055-1066.	1.1	3
811	Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102352.	3.4	17
812	Prognostic and immunotherapeutic significance of tumor- infiltrating M2 macrophages in muscle-invasive bladder cancer. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
813	Tumor ⁺ infiltrating lymphocytes in breast FNA biopsy cytology: a predictor of tumor ⁺ infiltrating lymphocytes in histologic evaluation. <i>Cancer Cytopathology</i> , 2022, , .	1.4	3
814	Limitations and opportunities for tumor infiltrating lymphocytes in breast FNA. <i>Cancer Cytopathology</i> , 2022, , .	1.4	0
815	Organ-on-a-chip platforms as novel advancements for studying heterogeneity, metastasis, and drug efficacy in breast cancer. , 2022, 237, 108156.		12

#	ARTICLE	IF	CITATIONS
816	Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring. <i>Frontiers in Immunology</i> , 2022, 13, 794175.	2.2	13
817	Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. <i>World Journal of Surgical Oncology</i> , 2022, 20, 38.	0.8	5
818	Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 1087.	1.7	7
819	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	0.8	5
820	Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 824166.	1.3	2
821	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
822	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 165, 664-670.	0.6	7
823	Clinical trial data and emerging strategies: HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 281-291.	1.1	12
824	Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101753.	1.6	19
825	The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer. <i>Surgical Oncology</i> , 2022, 41, 101725.	0.8	2
826	Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151930.	0.6	4
827	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	3.2	4
828	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. <i>Cancers</i> , 2021, 13, 6273.	1.7	9
829	Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. <i>Breast</i> , 2022, 62, S29-S33.	0.9	7
830	Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC. <i>Cancers</i> , 2022, 14, 121.	1.7	7
832	Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. <i>Cancers</i> , 2021, 13, 6352.	1.7	2
833	Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment. <i>Nutrients</i> , 2022, 14, 79.	1.7	15
834	The ratio of CD8+ lymphocytes to tumor-infiltrating suppressive FOXP3+ effector regulatory T cells is associated with treatment response in invasive breast cancer. <i>Discover Oncology</i> , 2022, 13, 27.	0.8	10

#	ARTICLE	IF	CITATIONS
835	Apparent diffusion coefficient and intravoxel incoherent motion-diffusion kurtosis model parameters in invasive breast cancer: Correlation with the histological parameters of whole-slide imaging. <i>Magnetic Resonance Imaging</i> , 2022, 90, 53-60.	1.0	6
836	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	0.8	139
840	Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12750-12762.	0.0	0
841	Role of immune system in TNBC. , 2022, , 121-148.		8
842	Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	9
843	Necroptosis-Associated lncRNA Prognostic Model and Clustering Analysis: Prognosis Prediction and Tumor-Infiltrating Lymphocytes in Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-18.	0.6	12
844	The Effect of Intratumoral Interrelation among FOXP3+ Regulatory T Cells on Treatment Response and Survival in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2138.	1.7	4
845	Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
846	Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy. <i>Veterinary Journal</i> , 2022, 283-284, 105833.	0.6	3
847	Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
848	Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	4
849	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
850	Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. <i>Cancers</i> , 2022, 14, 2692.	1.7	11
851	Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor sections. <i>Apmis</i> , 2022, 130, 545-550.	0.9	1
852	Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 231-241.	1.1	20
853	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
854	Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses. <i>Breast Cancer Research and Treatment</i> , 0, .	1.1	1
855	Recent progress in antibody-based therapeutics for triple-negative breast cancer. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 815-832.	2.4	4

#	ARTICLE	IF	CITATIONS
856	A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-23.	0.7	0
859	Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211126.	1.4	3
860	Prognostic Significance of Fibrotic Focus and Tumor Infiltrating Lymphocytes in Breast Cancer According to Molecular Subtypes. Journal of Breast Disease, 2022, 10, 18-28.	0.2	0
861	Immunological Landscape of HER-2 Positive Breast Cancer. Cancers, 2022, 14, 3167.	1.7	3
862	Immune checkpoint blockade in hormone receptor-positive breast cancer: Resistance mechanisms and future perspectives. Clinical Breast Cancer, 2022, , .	1.1	2
863	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers, 2022, 14, 3305.	1.7	11
864	Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
865	ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics. , 2022, 10, e004825.		9
866	Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer. Cancers, 2022, 14, 3650.	1.7	1
867	NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. Frontiers in Immunology, 0, 13, .	2.2	3
868	Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. Immunotherapy, 2022, 14, 957-983.	1.0	3
869	Can granulysin provide prognostic value in primary breast cancer?. Pathology Research and Practice, 2022, 237, 154039.	1.0	2
871	Immunology and immunotherapy in breast cancer. Cancer Biology and Medicine, 2022, 19, 609-618.	1.4	10
872	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. Human Antibodies, 2022, , 1-20.	0.6	0
873	Immunologic determinants of mammary tumors: PD-L1 and TILS. Revista De Senologia Y Patologia Mamaria, 2022, 35, S60-S66.	0.0	0
874	Editorial: Advancements in immunology and immunotherapy for breast cancer. Frontiers in Oncology, 0, 12, .	1.3	1
875	The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively. Journal of Medical Ultrasonics (2001), 2022, 49, 709-717.	0.6	2
877	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes and Diseases, 2023, 10, 1318-1350.	1.5	11

#	ARTICLE	IF	CITATIONS
878	CD39 ⁺ tissue-resident memory CD8 ⁺ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	23
879	Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8878.	1.8	5
880	Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer. <i>Current Oncology</i> , 2022, 29, 6154-6166.	0.9	7
881	Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors. <i>Clinical Breast Cancer</i> , 2022, 22, e901-e915.	1.1	5
882	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
883	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. <i>Journal of Controlled Release</i> , 2022, 349, 844-875.	4.8	22
884	Exploration of shared TF-miRNA-mRNA and mRNA-RBP-pseudogene networks in type 2 diabetes mellitus and breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
885	Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29887.	0.4	4
886	Stromal Tumor Infiltrating Lymphocytes (sTILs) Were Associated with a Higher Grade and a Lower Stage of Indonesian Triple Negative Breast Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2749-2754.	0.5	0
887	Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4494-4508.	3.2	5
888	Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
889	Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
890	Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer. <i>Cancers</i> , 2022, 14, 4561.	1.7	1
891	Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis. <i>Breast</i> , 2022, 66, 97-109.	0.9	11
892	The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer. , 2022, , .		0
893	Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2 ⁺ Negative Postmenopausal Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 4844.	1.7	2
894	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. , 2022, 10, e005119.		8
895	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. <i>Cancers</i> , 2022, 14, 4885.	1.7	5

#	ARTICLE	IF	CITATIONS
896	Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	24
897	Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining. <i>Biotechnic and Histochemistry</i> , 2023, 98, 147-154.	0.7	1
898	CD8+ T cell metabolic changes in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166565.	1.8	0
899	<sc>SPARC</sc> in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. <i>International Journal of Cancer</i> , 2023, 152, 1243-1258.	2.3	12
900	CXCL12, a potential modulator of tumor immune microenvironment (TIME) of bladder cancer: From a comprehensive analysis of TCGA database. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
901	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. <i>International Immunopharmacology</i> , 2022, 113, 109444.	1.7	6
902	Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy: A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. <i>Cancers</i> , 2022, 14, 5635.	1.7	3
903	Less Common Triple-Negative Breast Cancers. , 2022, , 463-573.		0
904	Understanding and harnessing triple-negative breast cancer-related microbiota in oncology. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
905	Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 391-403.	1.0	1
906	The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. <i>Cancer Discovery</i> , 2023, 13, 23-40.	7.7	35
907	Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. <i>Oncologist</i> , 2023, 28, 116-122.	1.9	4
908	Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
909	Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 6034.	1.7	6
910	Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
911	The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study. <i>Annals of Translational Medicine</i> , 2023, 11, 45-45.	0.7	2
912	The Future of Nanomedicine. <i>Micro/Nano Technologies</i> , 2023, , 847-873.	0.1	0
913	Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
914	¹⁸ F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Tumor Immune Microenvironment Function in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2023, 43, 127-136.	0.5	3
915	Tumor immunology. , 2023, , 245-452.		0
916	Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211461.	1.4	5
917	Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy. <i>Molecular Oncology</i> , 2023, 17, 1060-1075.	2.1	0
918	Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer. <i>Frontiers in Artificial Intelligence</i> , 0, 6, .	2.0	0
920	Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. <i>Cancers</i> , 2023, 15, 767.	1.7	13
921	Comparison of the prognostic value of stromal tumor-infiltrating lymphocytes and CD3+T cells between schistosomal and non-schistosomal colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	0
922	Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1569-1581.	3.2	8
923	Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
924	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. <i>Cancers</i> , 2023, 15, 1164.	1.7	4
925	Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
926	ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations. <i>Cancers</i> , 2023, 15, 1199.	1.7	3
927	Prognostic significance of tumour infiltrating lymphocytes in different molecular subtypes of invasive breast carcinoma. <i>Genes and Cells</i> , 2020, 15, 89-95.	0.2	0
928	Tailoring therapies to counter the divergent immune landscapes of breast cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	3
929	Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	5
930	Blocking soluble TNF± sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. , 2023, 11, e005325.		6
931	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
932	Adaptive immune receptor features related to breast cancer tissue in Kenyan patients: high immunoglobulin gene expression and high levels of gamma-delta T-cells. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0

